The Bloomberg BNA Intellectual Property Blog is the home of the "Do You Copy?" podcast and offers links to selected articles by the BNA IP team, which is accessible to both subscribers and non-subscribers as well as commentary and analysis exclusive to this blog.
Friday, July 27, 2012
by Anandashankar Mazumdar
Podcast (stream or download):
In Episode 31 of the "Do You Copy?" Podcast, Ananda and Tony talk about the recent oral arguments before the Federal Circuit in the Myriad case and also talk about a Third Circuit decision that bucks a trend and finds that "pay-for-delay" deals between brand name and generic drug makers violate antitrust law.
Tony previously blogged about the Myriad arguments. Dana Elfin's report on the Third Circuit's antitrust ruling is available here.
You must Sign In or Register to post a comment.
Goodlatte and Leahy Begin Patent Reform Round Two With Legislation Discussion Draft
Second Circuit Reinstates Trademark Claim Against Oprah Over ‘Own Your Power' Mark
Supreme Court: Supreme Court Grants Cert on Question of Standing in False Advertising Claims
Obama Joins Campaign Against Patent Trolls; Directs PTO Rulemaking, Suggests Legislation
Intellectual Ventures: Sells patent but keeps the proceeds